T cells bearing a chimeric antigen receptor against prostate-specific membrane antigen mediate vascular disruption and result in tumor regression.

@article{Santoro2015TCB,
  title={T cells bearing a chimeric antigen receptor against prostate-specific membrane antigen mediate vascular disruption and result in tumor regression.},
  author={Stephen P. Santoro and Soorin Kim and Gregory T. Motz and Dimitrios Alatzoglou and Chunsheng Li and Melita B. Irving and Daniel James Powell and George Coukos},
  journal={Cancer immunology research},
  year={2015},
  volume={3 1},
  pages={68-84}
}
Aberrant blood vessels enable tumor growth, provide a barrier to immune infiltration, and serve as a source of protumorigenic signals. Targeting tumor blood vessels for destruction, or tumor vascular disruption therapy, can therefore provide significant therapeutic benefit. Here, we describe the ability of chimeric antigen receptor (CAR)-bearing T cells to… CONTINUE READING